Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. 더 보기
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc...
PITTSBURGH, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious...
PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York...
Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouthNo FDA-approved therapy currently exists for OLPPatient registry and OLP study...
LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancerNovel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0849 | -17.6214196762 | 0.4818 | 0.5 | 0.39 | 237408 | 0.45556489 | CS |
4 | 0.0039 | 0.992366412214 | 0.393 | 0.54 | 0.355 | 870353 | 0.44708452 | CS |
12 | -0.1112 | -21.885455619 | 0.5081 | 1.5 | 0.3234 | 3907250 | 0.84614477 | CS |
26 | -0.2771 | -41.1127596439 | 0.674 | 1.5 | 0.3234 | 1837345 | 0.84347537 | CS |
52 | -1.1931 | -75.0377358491 | 1.59 | 2.71 | 0.3234 | 1134901 | 1.05421839 | CS |
156 | -6.6231 | -94.3461538462 | 7.02 | 7.72 | 0.3234 | 777830 | 1.40023937 | CS |
260 | -6.6231 | -94.3461538462 | 7.02 | 7.72 | 0.3234 | 777830 | 1.40023937 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관